NEW YORK, Nov. 20, 2023 /PRNewswire/ -- Voltron Therapeutics, Inc., a Lucius Partners portfolio company, today announced that it has finalized the protocol for a Dose-Ranging Efficacy Study of VTX-0P4, a protein-based cancer vaccine targeting Prostate Stem Cell Antigen (PSCA). PSCA is a key target in the treatment of Prostate Cancer. The ability of the SAV to target full proteins, as well as peptides, demonstrates that Voltron's vaccine platform has the potential to target dozens of oncology and infectious disease targets – collectively multi- billions of dollars of market potential. The pre-clinical trial is expected to commence in December.
NEW YORK, Sept. 26, 2023 /PRNewswire/ -- Voltron Therapeutics, a Lucius Partners portfolio company, presented new evidence that demonstrates its VaxCelerate Vaccine platform's superiority in driving effective T cell responses against lethal viral pathogens at the August 2023 Military Health System Research Symposium (MHSRS) in Orlando, Florida. The MHSRS is the Department of Defense (DoD)'s largest scientific meeting and is designed to highlight new scientific approaches to address DoD research priorities.
NEW YORK, Feb. 28, 2023 /PRNewswire/ -- Voltron Therapeutics, Inc, a Lucius Partners portfolio company, announced today that it has signed a new Sponsored Research Agreement (SRA) with the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH), Harvard Medical School to initiate a pre-clinical immuno-oncology trial targeting prostate stem cell antigen (PSCA) in prostate, renal cell and urothelial cancers, adding important potential indications to its growing pipeline.
NEW YORK, Oct. 26, 2022 /PRNewswire/ -- Voltron Therapeutics, a Lucius Partners portfolio company, announced the company's poster on its proprietary Self-Assembling Vaccine platform was selected for presentation and discussed at the Military Health System Research Symposium (MHSRS).
Voltron Therapeutics, Inc., a Lucius Partners portfolio company, today announced that data from the previously announce Study '098 demonstrated clear ...